SynthesisEuropean journal of clinical pharmacology2026
Ketamine and esketamine during breastfeeding: a systematic review of human pharmacokinetic, infant and lactation outcomes.
Synthesis in European journal of clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeKetamine is used in anaesthesia and analgesia, and esketamine nasal spray is licensed as a rapidly acting treatment for treatment-resistant depression; both uses overlap with the postpartum period. We synthesised human evidence on transfer into milk, infant exposure, infant outcomes and breastfeeding outcomes.
methodsThe review was registered in PROSPERO (CRD420261364557) and reported according to PRISMA 2020. Databases and registers were searched from inception in January 2026; supplementary sources and citation searching were completed on 21 August 2026. Eligible primary human reports measured drug or metabolite concentrations in human milk, outcomes in breastfed infants, or lactation outcomes after postpartum exposure. Certainty was rated with GRADE principles separately for each of these questions and for infant systemic exposure. Pooling was not undertaken because the studies were not comparable.
resultsSixteen reports were included. Three provided milk pharmacokinetic data from nine participants, all exposed to racemic ketamine; ketamine relative infant doses ranged from 0.34% to 0.77% and norketamine from 0.29% to 0.95%. No study measured infant plasma concentrations or long-term neurodevelopment. Perioperative studies showed no consistent adverse breastfeeding signal, but these secondary outcomes reflect maternal recovery and carry no information on infant exposure. No study quantified exposure during repeated intranasal esketamine.
conclusionTransfer of single or intermittent racemic ketamine into mature milk is below the conventional 10% threshold with moderate certainty, whereas certainty on infant systemic exposure and infant outcomes is very low. The findings do not cover chronic treatment and cannot be extrapolated to repeated intranasal esketamine.
Indexed as
Identifiers
42850468What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.